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The goal of this study is to evaluate the differences in readability and content between 
U.S. drug Package Inserts (PI) and Consumer Medical Information Leaflets (CMI).  
Using text mining techniques such as Natural Language Processing with the UMLS 
MetaMap, and document metrics such as the Flesch-Kincaid grade level score, a sample 
of PI and CMI will be examined for 35 common drugs in the U.S.  
 
Text Mining allows for mapping of text into Concept Unique Identifiers, which allows 
for comparison of text between documents with different vocabularies.  As Package 
Inserts are written for professionals, and CMI Leaflets are written for consumers, this 
technique lends itself well to compare content. 
 
This study shows that recall is appropriately low when comparing CMI Leaflets to 
Package Inserts: omitted concepts are more important for physicians and pharmacists 
than patients.  Readability is high for CMI Leaflets, but more effort should be made to 
express contraindications. 
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INTRODUCTION  
 A patient waits in his local pharmacy for his prescription to be filled.  While he 
waits, the pharmacist performs a series of steps to get the patient his medication.  The 
pharmacist verifies that the drug dosage is appropriate, checks the patient's record in the 
pharmacy database to make sure there are no obvious reasons the patient should not be 
given the drug, such as allergies, and measures the amount to be dispensed.  The 
pharmacist then applies information to the bottle, applying directions and warnings via an 
array of stickers, and then hands it to the pharmacy technician.  The technician prints a 
leaflet with more information about the prescription for the patient, staples it to the bag, 
and asks the patient if he has any questions about the prescribed drug while he pays for it.  
The patient likely assumes he has been told all pertinent information he requires to take 
the medication properly, and can reference the leaflet at a later time if necessary.  
The routine is virtually the same for millions of Americans: a patient visits his 
doctor, who examines and tests him, and produces a diagnosis. When a drug is 
appropriate to treat the condition, the doctor will write a prescription.  He chooses the 
course of therapy to be prescribed based on the drugs available for the patient’s 
condition, as well as the patient’s medical history, including any allergies.   
 In this study, Consumer Medical Information (CMI) Leaflets will be evaluated 
for completeness and readability and compared to Package Inserts (PI) as the gold 
standard.  CMI contains a summary of precautions and instructions for the drugs a patient 
has been prescribed, and is information often printed at the pharmacy counter.  The CMI 
is information generally bought by the pharmacy from an outside company, which bases 
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the summary on the PI.  The PI is an FDA-approved document written for health 
professionals by the drug manufacturer that contains detailed information about the drug 
produced and is included in the packaging.   
To accomplish the comparison of these two documents, the experiment will use 
Computational Linguistics techniques such as text mining and Natural Language 
Processing (NLP).  MetaMap, a Unified Medical Language System (UMLS) tool hosted 
by the National Library of Medicine will be used for NLP, and the Flesch-Kincaid grade 
level score will be used to measure readability.   
The following research questions will be addressed: 
1. How does the information in the Package Insert differ from the information in 
the CMI Leaflet? 
2. How do Package Inserts and CMI Leaflets compare in readability? 
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LITERATURE REVIEW 
The flow of drug information to the consumer is complex.  Sources of information 
directly provided to consumers include: doctors, pharmacists, Package Inserts, and CMI 
Leaflets.  A combination of any of these resources may be used by consumers, and these 
information sources all transfer information differently.   
Package Inserts are the de facto standard of publicly available, FDA-approved 
written information about prescription drugs.  However, they are sufficiently difficult to 
read to be considered significantly above the threshold of comprehensibility of the 
average consumer.  They contain all information required by professionals who prescribe 
and advise patients about how they may use the drug.  By law, they are distributed by the 
pharmaceutical manufacturer with every prescription drug they produce that is sold in the 
United States (FDA, June 2009).  
In response to the consumer’s need for drug information to accompany their 
prescriptions, as well as increasing requirement for patient counseling, many pharmacies 
began to distribute CMI Leaflets with prescriptions in the early 1990’s.  CMI Leaflets are 
designed to be an easily read resource which relays how to safely use prescribed 
medications.  These leaflets are not required by law, but are widely distributed as a self-
regulatory effort, following FDA recommendations.  Information in the leaflets is 
generally based on the FDA-approved Package Insert and the leaflets are distributed by a 
variety of information publishers.  However, as their content is not regulated by the FDA, 
the format, quality, and usability of these documents varies. 
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The Physician’s Desktop Reference (PDR) is a compendium that is used as a 
primary source of drug information for physicians.  It is published by a private-sector 
publisher, Thomson Medical Economics, and was originally conceived as a promotional 
publication for drugs.  Pharmaceutical companies are not legally required to submit 
information about their drugs to the publisher of the PDR, but do so willingly as a basic 
type of drug marketing process.  As the PDR is a commercial product, drug companies 
must pay to be included in the publication.  The publisher also states that the drug 
manufacturers are solely responsible for the accuracy of the information submitted for 
publication (Thornton, 2003).  As there is little regulatory control over this compendium, 
there is some potential cause for concern as to the accuracy of the information published 
(Cohen, 2001). 
Information flow for patients generally originates from the prescribing physician, 
who typically advises the patient of the new prescription, and provides varying degrees of 
details about the medication to the patient.  When a patient has a prescription filled at a 
pharmacy, the patient may ask to consult with the pharmacist.   The pharmacist may have 
additional information including possible drug interactions or special precautions, and the 
patient is given written information such as the CMI Leaflet, and possibly the Package 
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Insert. Figure 1 summarizes these information flows.
 
Figure 1: Possible flows of drug information to consumers 
An assumption in this information flow is that physicians know the patient’s 
histories, allergies, and other mitigating factors in prescribing a therapy and the 
pharmacist will have records of other prescriptions, to help prevent drug-drug 
interactions, if applicable.  However, this assumption is over-simplified.   
Given that patients in the U.S. generally do not exclusively see one doctor, each 
individual physician that sees the patient may not have a complete patient history and full 
knowledge of a patient’s co-occurring therapies.  Patients may also have prescriptions 
filled at several pharmacies.  Some health insurance policies require patients to fill some 
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prescriptions, particularly long-term medications, through a pharmacy of the company’s 
choice, rather than the patient’s.   
Additionally, many long-term prescriptions are filled using mail order pharmacies 
which potentially have no pharmacist-patient interaction, relying completely on written 
counseling.  Because medications are being dispensed by multiple pharmacies, 
pharmacists may not be aware of dangers, such as potential drug interactions, which the 
patient may be exposed to. 
Patients who see multiple doctors or pharmacists cannot assume that all relevant 
information is being given to them for every drug they are prescribed, as their physicians 
and pharmacists may not have complete information of the patient.  Therefore, patients 
must play an active role in acquiring drug information for themselves.   
Initially, the FDA required “Patient Package Inserts” (PPI), consumer-readable 
information about the drug included with the Package Inserts (PI) for selected drugs in 
1968. Research had shown a correlation between extensive use of the drug isoproterenol 
and the condition bronchoconstriction, which prompted the FDA to mandate a brief 
warning be affixed to its container.   In 1970, the FDA required that a PPI accompany 
oral contraceptives when research showed an association between use of oral 
contraceptives and various circulatory disorders. Since oral contraceptives, once 
prescribed, were administered without significant medical supervision, the FDA 
concluded that patients needed a PPI that directed them to obtain a more detailed 
information pamphlet from their physician.  This information was to supplement 
professional advice, but not replace it (Schuman, 2002). 
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The AMA was particularly opposed to the PPI program.  At the time, many 
physicians supported a theory that the potential for suggestibility was heightened by 
presenting patients with information about a drug’s potential side-effects.  If the PPI 
included with medication states that the drug may cause headaches, for example, it might 
cause patients to have psychogenic headaches simply because the PPI says it is possible 
for the patient to have that symptom due to the use of the drug (Keyown, Slovic, 
Lichenstein 1984).  Studies conducted at the time of this debate about public availability 
of drug information, such as the Keown, Slovic and Lichtenstien study, showed that 
psychogenic or “suggested” side-effects were uncommon.  However, while patients were 
not shown to imagine suggested symptoms, patients were more likely to attribute 
symptoms, possibly unrelated to their medication, as a side-effect of the medication 
(Morris, 1981). 
 Another reason for opposition to mandatory regulated PPI’s was the concern that 
pharmacists would be intruding unnecessarily into the patient/physician relationship and 
diminish the physician’s role in the drug prescription process.  The stance of the FDA 
was that the PPI program was not intended to replace the physician, rather it was intended 
to supplement individual instruction. 
The FDA began a 3-year pilot program to extend the PPI requirement for all drugs 
in 1979.  At the end of the program in 1982, the FDA opted to withdraw its governance 
of PPI in favor of private-sector self-regulated control of drug information for consumers 
(Svarstad, Mount, Tabak, 2005).  This action was endorsed by such organizations as the 
American Medical Association (AMA), the American Association of Retired Persons 
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(AARP), National Council on Patient Information and Education (NCPIE), and the 
Committee on Patient Education, a FDA entity (Schluster, 1995).   
As computer technology advanced in the early 1990’s, pharmacies began printing 
leaflets for patients with new prescriptions, now referred to as Consumer Medicine 
Information (CMI).  These were intended to address increasing state and federal 
requirements for patient counseling at pharmacies.  However, the quality of these earlier 
leaflets were largely deemed deficient by the FDA due to poor quality of provided 
information, patient non-adherence, poor patient knowledge and preventable adverse 
reactions (Svarstad, Mount, Tabak, 2005).  Counseling requirements evolved on the state 
and federal levels because of the perceived complexity of the Package Inserts, which 
mainly focused on informing professionals, rather than consumers, about the products.   
Due to the increase in counseling requirements, there was a subsequent increase 
in written information, and the fact that the quality of the written information was largely 
unregulated was questioned by DHHS.   Congress requested DHHS develop an action 
plan to evaluate the extent of this potential problem and authorized the FDA to create an 
action plan to address deficiencies.  The evaluation plan was developed in August, 1996 
and was steered by a committee of professionals and consumers from 34 different 
organizations.  The resulting plan became known as the Keystone Criteria (Svarstad, 
Mount, Tabak, 2005). 
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Criterion The information must: 
1 Include drug names and indications for use 
2 Include contraindications and what to do if applicable 
3 Include specific directions about how to use, monitor, and get the most 
benefit 
4 Include specific precautions and how to avoid harm while using it 
5 Include symptoms of serious or frequent adverse reactions and what to do 
6 Include general information and encouragement to ask questions 
7 Be scientifically accurate, unbiased, and up-to-date 
8 Be readily comprehensible and legible 
Table 1: Keystone Criteria for Consumer Medical Information (Kimberlin, Winterstein, 
2008) 
 Several studies have been done, not just in the U.S., but also internationally, 
regarding the quality of prescription information provided to consumers.  While 
consumers had access to the professional package insert and were often given CMI 
leaflets from pharmacies, patients still were not getting the necessary drug information 
about their prescriptions well into the 2000’s.  
The need for supplemental instruction for patients was illustrated in a study by 
Lapointe, Pappas, Deverka, et al. (2006). Consumers were surveyed about information 
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they had received with Isotretinoin and Estrogen prescriptions.  They found that 86% of 
patients received the FDA-Approved Package Insert, and 75% of the 300 participants felt 
confident they knew all the information necessary to take their prescribed medication.  
However, when tested about their knowledge of their prescribed drug, they were unaware 
of many of the risks of their medication. 
Participants were given a questionnaire in which they were to answer “yes” or 
“no” to five side effects or risks associated with their medication.  Their results showed 
that the mean number of correct responses scored only slightly higher than the threshold 
achieved from guessing.  Fewer than half of the participants knew about the most severe 
side effects, myocardial infarction and cancer, despite having read the Package Insert or 
the FDA Medication Guide. 
A 2007 study compared the leaflets given to patients in pharmacies in the U.S., 
the U.K., and Australia (Raynor, Svarstad, Knapp, et al., 2007).  A set of four drug 
leaflets from each area was selected, for four drugs: atenolol, atorvastatin, glyburide, and 
nitroglycerine.  The rating process was conducted manually by two health services 
researchers and three pharmacist health service researchers.  Using the U.S. Keystone 
guidelines, each drug’s leaflet was evaluated by each evaluator for Keystone Criterion 1-
6.  Since Keystone Criteria 7 and 8 are somewhat subjective, all documents were assessed 
on these two criteria by one reviewer, and moderated by another reviewer. 
It was found that even with the new U.S. Keystone guidelines for information in 
leaflets, U.S. CMI Leaflets were still deficient in the information they provided.  The 
most frequently omitted information was regarding drug interactions, but they also were 
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lacking in listing specific precautions.  However, the U.S. was not alone, as Patient 
Leaflets in the U.K. rated similarly as a whole. (Raynor, Svarstad, Knapp, et al., 2007). 
 A study was also done that directly used the Keystone Criteria to evaluate CMI 
Leaflets (Svarstad, Mount, Tabak, 2005).  Experimenters obtained CMI Leaflets from a 
variety of pharmacies and in a variety of geographical areas for a fixed list of prescription 
drugs. The experiment was designed this way in order to obtain the best random sample 
from all different types of pharmacies, from small independent drug stores to large chain 
stores.  Each leaflet was evaluated manually by experts for congruence between the 
leaflet and the FDA-approved Package Insert, and also evaluated by consumers for 
readability.  Though the consumer evaluators were satisfied overall with the information, 
the expert evaluators rated most leaflets as deficient in all Keystone Criteria, with 
complete agreement that no leaflets reached the “high quality” mark of 80% or higher 
compliance with the Criterion. 
 Though several studies have been done to evaluate consumer prescription drug 
leaflets, they have all used expert evaluators using manual methods of evaluation based 
on their own experience. In review of pertinent literature, there were no references to 
attempts at evaluating these criteria automatically.  The criterion for evaluation of 
consumer prescription drug information is well-formed, well-defined, and ready for an 
automated tool to rate to these criterion as humans would.   
 In a recent study by Bashyam and Taira (2009), MetaMap 
(http://mmtx.nlm.nih.gov), a Natural Language Processing (NLP) tool was used to code 
clinical concepts in clinical reports.  To do this, the word elements in the documents were 
mapped to UMLS Concept Unique Identifiers (CUI) as a step to normalize word tokens 
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for comparison.  The Concept Unique Identifier is a label for unique concepts in the 
UMLS.  Each concept is associated with a semantic type, as well as a definition and any 
synonyms (see Table 2).  The advantage of using this approach is that the problem of 
different word ordering and synonymy of concepts is solved by eliminating the 
complexities of language, and storing the contents as a bag-of-concepts instead. Using 
this method, the authors were able to accurately compare two documents at the 
conceptual level, rather than at the syntactic and lexical levels. 
 
Term Name Hypertensive disease 
CUI C0020538 
Definition Persistently high systemic arterial BLOOD PRESSURE. Based on 
multiple readings (BLOOD PRESSURE DETERMINATION), 
hypertension is currently defined as when SYSTOLIC PRESSURE 
is consistently greater than 140 mm Hg or when DIASTOLIC 
PRESSURE is consistently 90 mm Hg or more. (MSH)  
persistantly high arterial blood pressure. (CSP)  
Abnormally high blood pressure. (NCI)  
Pathological increase in blood pressure; a repeatedly elevated blood 
pressure exceeding 140 over 90 mmHg. (NCI) 
Synonyms Vascular Hypertensive Disorder 
vascular hypertension 
systemic hypertension 
Systemic arterial hypertension 
Raised blood pressure (disorder) 
Pressure, high blood 
Increased blood pressure 
Hypertensive vascular disease 
Hypertensive vascular degeneration 
Hypertensive disorder, systemic arterial (disorder) 
Hypertensive disorder 
HYPERTENSIVE DISEASES 
Hypertensive disease, NOS 
Hypertensive disease NOS (disorder) 
Hypertensive disease NOS 
Hypertensive disease 
Hypertensive cardiovascular disease or syndrome 
Hypertension, NOS 
Hypertension, arterial 
Hypertension NOS 
HYPERTENSION ARTERIAL 
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Table 2: Data associated with the CUI representing “Hypertension” 
 
The main benefit to automated evaluation is that it is potentially much less 
expensive, faster, and can evaluate a larger corpus. This experiment will attempt to use 
novel text mining techniques as an automated process to evaluate consumer prescription 
drug information using the Keystone Criteria as a guide.  
Hypertension 
Hyperpiesis 
Hyperpiesia 
HTN - Hypertension 
htn 
HT - Hypertension 
HT 
high; blood pressure 
high; arterial tension 
high bp 
High Blood Pressures 
High blood pressure disorder 
High blood pressure (& [essential hypertension]) 
High Blood Pressure 
HBP - High blood pressure 
HBP 
BP+ - Hypertension 
BP - High blood pressure 
Blood Pressures, High 
blood pressure; high 
Blood Pressure, Increased 
Blood Pressure, High 
BLOOD PRESSURE HIGH 
3-02 HYPERTENSIVE DISEASES 
(Hypertensive disease) or (hypertension) 
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METHODOLOGY 
 
 The goal of the experiment is to use an automated text mining approach to 
compare the content and readability of CMI Leaflets to those of Package Inserts.  The 
experiment will use the Keystone Criteria (see Table 1) as standards for the overall 
quality of the leaflets.  Each of the Keystone Criterion can be evaluated objectively with 
an automated system, with the exception of criterion #7, “Information must be 
scientifically accurate, unbiased, and up to date.”  In order to address that criterion, a 
domain expert would be required to determine whether the leaflet complies; this criterion 
is not included in the study. 
Simple word comparisons or pattern matching are not sufficient for finding 
intersections between two documents, thus a text mining approach is needed.  The text 
mining tools used must be nimble enough to recognize matches between documents 
written in very different styles.  Package Inserts, as they are targeted at a professional 
audience, are likely to use different vocabulary than the CMI Leaflets, which are 
designed to be read by consumers.  Several other classic NLP problems exist in the text 
as well. 
One problem that is a common obstacle in text mining is dealing with synonymy.  
There are multiple ways to represent the same concepts in the English language.  Simple 
pattern matching can be useful in conjunction with stemming.  For example, the words, 
“testing”, “tests”, “tested” and “test” all have the same stem, “test”, and are essentially 
synonymous.  A stem is a root word from which other variations of the word are derived.  
It is then possible to match words from one document to the next by using the stemmed 
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word for pattern matching, and return a match regardless of the number or tense of the 
words.  
Synonymy can go beyond different words meaning the same concept, to include 
similar concepts.  For example, the terms “hypertension”, and “high blood pressure” are 
synonymous.  However, a simple pattern match between these two words would 
erroneously produce a negative result.   
Cimino refers to the “atomic approach” as a possible way to resolve synonymy in 
vocabulary.  Word atoms are single words which when put together can form word 
molecules.  Cimino uses the examples of the word molecules “White Conjunctiva” and 
“Wolff-Parkinson-White Syndrome” to illustrate this concept.  The atom, “White”, can 
refer to either the color white, or to the name “White.”   These atoms must be put in a 
molecular context in which the terms actually name a concept, not just exist as words 
which potentially have multiple meanings (Cimino, 1998). 
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Another problem is the comparison process in which terms from one document 
are to be matched to another document that is similar, but likely structured differently.  
This experiment will avoid the problems of lexical-level comparison by mapping words 
to CUIs, thus transforming the task into concept-level comparison.  The problems of 
comparing differing sentence and paragraph structures in this experiment are avoided by 
treating each document as several bags of concepts in the form of CUIs.  Each document 
is mapped to equivalent sections and each section is treated as a bag of concepts for 
comparison. 
 
PI Heading Equivalent (First Databank) CMI 
Leaflet Heading 
Description n/a 
Microbiology and Clinical 
Pharmacology 
General Information 
Indications and Usage Uses 
Warnings Warnings 
Precautions Precautions 
Adverse Reactions Side Effects 
Overdosage Overdose 
Dosage and Administration How to Use 
How Supplied n/a 
Table 3: Package Insert headings with corresponding CMI  
Leaflet headings 
As shown in Table 3, the overall structure of Package Inserts and CMI Leaflets 
produced by First Databank is fundamentally similar.  The differences between the two 
documents are mainly noted in the “Description” and “How Supplied” sections.  The 
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“Description” heading describes the drug at the chemical level, including chemical and 
structural formulas, and inert ingredients.  The “How Supplied” section lists all forms of 
the medicine, such as: capsule, tablet, or liquid.  These two sections are useful for health 
professionals, but not necessarily relevant to consumers, which is why they do not map to 
CMI Leaflet sections. 
The “Microbiology and Clinical Pharmacology” section offers details about what 
biological mechanisms the drug uses, and also shows details of their clinical studies.  
While most of the information in this section is not particularly useful to consumers, part 
of this information is used in the “General Information” section of the CMI Leaflet.     
To accomplish an inter-document comparison where the various documents are 
expected to use different vocabularies, a content analysis will be conducted using a text 
mining tool, MetaMap 2009 v2, which uses natural language processing and 
computational linguistic techniques.  MetaMap is a Unified Medical Language System 
(UMLS) tool which is published by the National Institute of Health and the National 
Library of Medicine (Aronson, 2001).  While it is used for information retreival and data 
mining, it is also used as a Medical Text Indexer, which automatically indexes 
biomedical literature at the National Library of Medicine.  The UMLS contains a 
semantic network of terms in the metathesaurus.  The metathesaurus covers the medical 
domain, including an extensive inventory of chemistry, medicine, pharmacology and 
biological terminologies.   
MetaMap is a commonly used tool for Information Extraction (IE) for documents 
within the medical domain.  Hsieh, Hardardottir, and Brennan (2004) were able to extract 
the meanings of email sent from patients to nurses using MetaMap to extract concepts.  
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The experiment showed MetaMap correctly captured the concepts in email approximately 
53% of the time.   
Erdal, Ding, Osborn, et al. (2007), used Metamap to create a prototype system to 
extract diagnosis information from free-form medical text and transform it into the form 
of an ICD-9 code.  ICD-9 is a diagnosis code system which is used by medical facilities 
for billing.  The ability to automatically code medical text for medical record coding 
specialists allows for a measure of quality control, as well as expediting coding and 
billing. 
Pratt and Yetisgen-Yildiz (2003) showed that MetaMap was not only a viable tool 
for identifying concepts within unstructured text, but also could perform near the ability 
of a human.  Their results suggest that MetaMap performed very well in the task of 
mapping common biomedical terms from free-form text.  Its limitations were found to be 
concepts which were absent from the UMLS Metathesaurus, which drives MetaMap. 
Chapman, Fiszman, Dowling, et al. (2004) used MetaMap to identify up to 71 
clinical conditions from medical records which may potentially indicate lower respiratory 
syndrome, a condition which has public health implications.  By using the CUI encoding, 
the experimenters were able to identify symptoms that were stated differently by different 
patients and that were coded differently by different doctors, in order to recognize when a 
patient could potentially have the targeted condition.  The limitation of MetaMap in this 
study was found to be the resolution of abbreviations such as “pO2” instead of “percent 
oxygen”, for example. 
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MATERIALS 
 
 There are two distinct sets of data for this experiment: the Package Inserts 
and the CMI Leaflets. The Package Inserts were collected from the “Drugs@FDA” web 
site, which is an official repository of FDA-approved package inserts for drugs approved 
after 1998.  Package Inserts are available on the Drugs@FDA web site in the form of 
PDF documents. 
CMI Leaflets are not as closely regulated as Package Inserts; they are not hosted 
by any of the FDA’s web sites. Several commercial information sources exist for CMI 
Leaflets.  Which CMI Leaflet the consumer will encounter largely depends on the 
pharmacy they go to fill their prescription.  A list of top grossing pharmacies was found 
at an online chain drug store industry news resource (Chain Drug Review, 2009).  The 
top five pharmacies on this list in the United States as of 2009 were Walgreens, CVS 
Caremark, Wal-Mart, Rite Aid, and Kroger.     
Each of the top five pharmacies has online access to the CMI Leaflets they print 
for their customers.  The web sites of each of these five pharmacies was visited, and the 
Figure 2: Pharmacies and their leaflet data sources 
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source of the drug information provided to customers was identified (Fig. 2).  The data 
providers for the CMI Leaflets were identified as: Wolters Kluwer Health, Thomson 
Healthcare, Gold Standard, and First Databank.  Of these providers, First Databank, a 
subsidiary of The Hearst Corporation, is the largest provider of health information world-
wide.  In addition, First Databank is used as a drug summary resource on popular online 
health information web sites, such as WebMD and Medscape (WebMD, 2010) 
(Medscape, 2010).  First Databank leaflets were chosen for use as the representative CMI 
Leaflets not only for their prevalence in the marketplace, but also because of their 
consistency.  Every First Databank CMI Leaflet contains the sections listed in Table 4, 
which were easily mapped to Keystone Criteria. 
 
 
Heading Keystone Criteria 
COMMON BRAND NAME(s) #1: drug names and indications for use 
USES #1: drug names and indications for use 
HOW TO USE THIS MEDICATION #3: specific directions about how to use, monitor 
and get the most benefit 
SIDE EFFECTS #5: symptoms of serious or adverse frequent 
reactions and what to do  
PRECAUTIONS #4: specific precautions and how to avoid harm 
while using it 
DRUG INTERACTIONS #4: specific precautions and how to avoid harm 
while using it 
OVERDOSE #5: symptoms of serious or adverse frequent 
reactions and what to do 
NOTES #6: general information and encouragement to ask 
questions 
MISSED DOSE #3: specific directions about how to use, monitor 
and get the most benefit 
STORAGE #6: general information and encouragement to ask 
questions 
Table 4: First Databank CMI Leaflet headings ordered by where they appear in 
the document 
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Two of the Keystone Criteria, #7 and #8, are not shown in Table 4.  Criterion #7, 
“…scientifically accurate, unbiased, and up-to-date” did not map to any heading, and is 
not evaluated in this study.  It cannot be evaluated automatically with the methods used in 
this experiment; a human expert would be required to evaluate what is accurate, unbiased 
and up-to-date.   While Criterion #8, “…readily comprehensible and legible” did not map 
to a heading either, it will be evaluated on the documents as a whole, using the Flesch-
Kincaid Grade Level metric.   
 
PREPROCESSING 
 
For the purpose of this study, 35 Package Inserts were collected.   These inserts 
corresponded to the 35 most common prescription drugs filled in the U.S., based on 
overall quantity (Lamb, 2009).  The PI data for this experiment was collected from the 
Drugs@FDA web site, and CMI Leaflets from revco.com, which exclusively uses First 
Databank as the leaflet provider.  The quantity of drugs to be examined, 35, was 
determined as it is a number much greater than similar expert-evaluated studies which 
included five to six drugs, but a small enough number that it could be processed in a 
reasonable amount of time.  Since both the CMI Leaflets and Package Inserts were being 
examined, a maximum of 70 (35 leaflets + 35 inserts) documents would have potentially 
required processing.  However, generic drugs produced by multiple manufacturers had 
overlapping CMI leaflets.  Because these drugs have the same drug name but are 
manufactured separately, there were only 66 documents (31 leaflets + 35 inserts) 
processed in total. 
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 The documents were downloaded in PDF format and reduced to ASCII text by 
using “pdf2txt” software (http://www.pdf2txt.com). Charts and figures were removed 
from the corpus, as they could not properly be interpreted by MetaMap.  The documents 
were also filtered and stripped of Unicode characters.  MetaMap does not support non-
ASCII characters, which excludes Unicode.  These modifications to the data were 
completed using simple UNIX text processing tools such as awk, grep, sed, and cut.  The 
text was then reformatted for compatibility with MetaMap (see Figure 3). Each document 
was broken into six sections to correspond with Keystone Criterion 1-6.  The documents 
were then re-assembled into “MEDLINE” format (see Fig. 3), which is used by MetaMap 
for batch processing of data.  This formatting consisted of adding a 9-digit Unique 
Identifier ("UI"), a Title (“TI”), and an Abstract section labeled (“AB”), where the text of 
the section was located.  The UI was encoded based on the document type (1=PI,2=CMI), 
source (0=PI Manufacturer, 1=First Databank), drug (1-35), and section number (1-6) 
that corresponded to matching Keystone Criterion (see Table 4).  
UI  - 210200004 
TI – FUROSEMIDE – ORAL FDB pt4 
AB – DRUG INTERACTIONS:Your doctor or pharmacist may already be 
aware of any possible drug interactions and may be monitoring you for them.  
Do not start, stop, or change the dosage… 
Figure 3: Sample text changed to MetaMap format for processing 
METAMAP COMPARISON 
MetaMap was used to transform all 35 Package Inserts and 30 CMI Leaflets to 
UMLS CUIs.  A training set of five randomly-selected drugs from the corpus was used to 
determine which options to use with MetaMap.   The options selected to pass to 
MetaMap for processing include removing stop words and stop phrases, such as “and”, 
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“the”, “by”, and other common words which occur often but do not have significance by 
themselves.  MetaMap scores each of its matches based on the confidence of the match 
on a scale from 1 to 1000, with 1000 being the highest confidence.  An option was given 
to MetaMap to limit matches to those rating to a score of at least 600 out of 1000 points 
in order to eliminate poor matches.  The output from MetaMap was then uploaded into a 
database for analysis (see Fig. 4).   
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Drug Name Manufacturer
Advair Diskus GSK
Crestor AstraZeneca
Cymbalta Eli Lilly
Diovan Novartis
Effexor XR Wyeth
Lexapro Forest Laboratories
Lipitor Pfizer
Lisinopril LEK Pharmaceuticals
Nexium AstraZeneca
Plavix Bristol-Myers Squibb
Prevacid Takeda
Proair TEVA
Seroquel AstraZeneca
Simvastatin Dr Reddys Laboratories
Singulair Merck
Synthroid Abbott
Vytorin Merck/Schering-Plough
amlodipine besylate Mylan
amoxicillin TEVA
azithromycin Greenstone
azithromycin TEVA
cephalexin Mikart
furosemide Mylan
hydrochlorothiazide TEVA
hydrocodone bitartrate and acetaminophen Mallinkrodt (Coviden)
hydrocodone bitartrate and acetaminophen Watson
levothyroxine sodium Lannett Company
levothyroxine sodium Mylan
metformin hydrochloride TEVA
metoprolol tartrate Mylan
metroprolol succinate Ethex
oxycodone and acetaminophen Mikart
sertraline hydrochloride Greenstone
simvastatin TEVA
warfarin sodium TEVA  
Table 5: Drugs and manufacturers included for analysis 
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Figure 4: MetaMap analysis and bag-of-concepts comparison. 
 
Each concept in the UMLS is represented by a Concept Unique Identifier (CUI). 
Each concept is also classified as one of 132 semantic types represented in the 
metathesaurus.  By limiting results of MetaMap to relevant semantic types, performance 
can potentially be enhanced by eliminating some of the possibilities of multiple 
interpretations of phrases.  For example, the word, “ventilation” can mean two things: a 
human physiologic function, or environmental air flow.  By excluding the semantic type 
“environmental effect of humans,” only “respiration” is considered as a candidate term.  
Other irrelevant semantic types removed from consideration serve to increase the 
accuracy of the MetaMap results. Using the training set, 32 semantic types were 
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identified for exclusion in the data options passed to MetaMap, such as: algae, 
amphibians, birds, fish, invertebrates, plants, etc.  For example, concepts such as 
“amphibian” were unlikely to be used in either Package Inserts or CMI Leaflets. Table 6 
gives the list of excluded types. 
 
Alga Geographic Area Machine Activity Occupational 
Activity 
Physical Object Reptile 
Amphibian Government or 
Regulatory 
Activity 
Mammal Organism Plant Research Activity 
Animal Group Manufactured 
Object 
Organism Attribute Population Group Research Device 
Bird Intellectual Product Molecular 
Sequence 
Organism Function Professional 
Society 
Self-help or Relief 
Organization 
Eicosanoid Invertebrate Natural 
Phenomenon or 
Process 
Organo-
phosphorous 
Compound 
Professional or 
Occupational 
Group 
Temporal Concept 
Fish Language Occupation or 
Discipline 
Patient or Disabled 
Group 
Regulation or Law Vertebrate 
Table 6:  List of semantic types excluded by MetaMap 
 
The analysis of the data output from MetaMap consisted of a bag-of-concepts 
analysis.   For each of the Keystone Criteria 1-6, concepts extracted from the CMI 
Leaflets were compared to those extracted to the corresponding Package Inserts.  
 
MEASURING PERFORMANCE 
Though the system used in this experiment is not an information retrieval system 
per se, the concepts of precision and recall can be used to measure performance.  For this 
study, the Package Insert was considered the gold standard, essentially containing all 
relevant CUIs, as the CMI leaflet is a subset based on the information contained in the 
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Package Insert.  The system measures the recall of the CMI Leaflets, using the Package 
Insert as the gold standard.  Precision is defined as all CUIs created for CMI Leaflets also 
found in Package Inserts. 
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝑟𝑟 𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝
𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟 𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝 
𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟 = 𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟 𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝
𝑝𝑝𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟 𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝  
  Precision is not measured for this study, since the CMI Leaflet is a summary of 
the Package Insert, and only the intersecting CUIs per Keystone Criteria are being 
counted. Precision will always be perfect (100%) in this case.  As the CMI Leaflet is a 
subset of information based on the PI, it cannot contain more information than the 
original data, the Package Insert.  Recall is defined as all CUIs generated from CMI 
Leaflets divided by the total CUIs generated from Package Inserts.  Recall is expected to 
be quite low.  This is because the Package Insert is written for readers with extensive 
medical and pharmacological knowledge, and contains terms which should be excluded 
completely from the summarized CMI Leaflet.  
MEASURING READABILITY 
 Another dimension to consider for analysis is readability.  This corresponds to 
Keystone Criterion #8, “Be readily comprehensible and legible.”  To analyze this, the 
Flesch-Kincaid Grade Level was used.  The Flesch-Kincaid Grade Level metric is a 
representation of the readability of the document equivalent to the mean number of 
school years, or grades, needed to properly comprehend its content.  The grade level 
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produced by the metric is based on U.S. grade levels (Kincaid, Fishburne, Rogers, 1975).  
The Flesch-Kincaid Grade Level metric is calculated using the following formula: 
 
𝐺𝐺𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝 𝐿𝐿𝑝𝑝𝑟𝑟𝑝𝑝𝑟𝑟 = �0.39 × 𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟 𝑤𝑤𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝
𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟 𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝� + �11.8 × 𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟 𝑝𝑝𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟𝑠𝑠𝑟𝑟𝑝𝑝𝑝𝑝 𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟 𝑤𝑤𝑝𝑝𝑝𝑝𝑟𝑟𝑝𝑝 � −  15.59 
 
 To measure the Flesch-Kincaid score on the corpus, each document was 
preprocessed, with numbers and charts removed, as these would otherwise distort the 
syllable count.  After preprocessing, the words and syllables were counted.  The results 
were then entered into a database, where the grade level score formula was calculated for 
each document as a whole. 
 As it is estimated that 50% of adult Americans read at or below the 8th grade 
level, a Flesch-Kincaid Grade Level score of 8.5 or lower should be considered readable 
by adults. (U.S. Dept of Education, 2010)  It would thus be desirable for CMI Leaflets to 
meet that readability standard.  Package Inserts are written to comply with FDA rules and 
require FDA approval.  They are required to be thorough and contain information used 
for the approval process, including study information, and other pharmacology and 
medical terms which are not in the general public’s vocabulary.  Therefore, a much 
higher grade level readability score is anticipated for the Package Inserts. 
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RESULTS 
 The pre-processed corpus used in this study consisted of a total of 944,153 
words. Metamap generated 91,746 CUI instances from the corpus.   MetaMap CUI 
production showed Package Inserts producing significantly more CUI than CMI Leaflets, 
as expected (see Table 7).   
Table 8 shows recall for each drug broken out by criterion. The overall maximum 
recall was 29.9%, and minimum was 0.6%, (see Table 8).  Figure 7 shows a visualization 
of mean recall for each criterion. Patterns of particular interest can be found in Keystone 
Criteria 1, 2, an d 4, and will be discussed later.   
Table 7: CUI production per document type 
 Mean number of 
CUI per 
document 
Minimum number 
of CUI per 
document 
Maximum 
number of CUI 
per document 
CMI Leaflet 188 70 783 
PI 496 130 7051 
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Table 8: CUI recall for Keystone Criterion 1-6 for each drug 
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Figure 7: Summary of Recall of CUI by Keystone Criteria 
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Table 9: Mean, Minimum, and Maximum Recall  
for each drug 
 
 
Table 10: Mean, Minimum, and Maximum Recall  
for each criterion 
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 Figure 8 is a visualization of reading grade levels for the Package Inserts and CMI 
Leaflets in this study.  Differences in reading levels are shown between the two document 
types, as evidenced by two distinct columns of reading levels representing the CMI 
Leaflet at lower reading levels, and PI at higher reading levels.  The average grade 
reading levels were 8.75 for CMI Leaflets and 14.45 for Package Inserts. 
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Figure 8: Flesch-Kincaid reading grade level scores for CMI  
Leaflet and PI 
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DISCUSSION 
Criteron 1 is “drug name and indications for use.”  In many cases, the PI and CMI 
Leaflet recall levels differed among drugs as illustrated in Figure 7.  CMI Leaflets 
associated with drugs with a narrower scope of use acheived a higher recall percentage 
than average.   One example is Synthroid, a synthetic thyroid hormone replacement 
medication which only has one purpose.  It had a relatively high recall (mean: 15.17%, 
min: 9.12%, max: 27.6%), indicating that this section of the leaflet contained most of the 
CUIs used in the PI.  Amoxicillin, an antibiotic to treat infections, performed similarly.  
Furosemide, a drug with a broader scope of use as a diuretic used for treating a variety of 
conditions such as liver disease, kidney disease, heart disease, ranked lowest, at 2.0% 
recall.  The CMI Leaflet mentions some of the general uses of the drug, but the Package 
Insert lists all approved uses, which is a much larger list. 
Criterion 2 is “contraindications and what to do if applicable.”  The CMI Leaflets 
as a whole had very little information about contraindications.   The few that did have 
particularly dangerous contraindications ranked higher in recall for this criterion.  Drugs 
with special warnings of contraindications were likely to have a higher recall percentage.  
One example was Synthroid, which listed many over the counter (OTC) medications that 
could interfere with its absorption, or would adversely interact with it, found in the ”Drug 
Interactions” section of the CMI Leaflet. 
 Criterion 4 is “specific precautions and how to avoid harm while using it.”  The 
results shown in Figure 7 show a relatively flat recall across all the CMI Leaflets 
compared to the other criteria.  The reason for this is the prevalence of standardized 
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wording in the CMI Leaflet to address general precautions when using any medication.  
Individual differences in medications were the cause of the minor differences between 
drug CMI Leaflets, interjecting extra information within the standardized block of text. 
Another issue which is revealed in the pattern in Figure 7, criterion 4 appears to 
have a higher recall due to standardized wording used by the leaflet information company 
for this section. The following sample can be found in each drug’s “Precautions” section 
in the CMI Leaflet: 
“Before taking [DRUG], tell your doctor or pharmacist if you are allergic 
to it; or if you have any other allergies. This product may contain inactive 
ingredients, which can cause allergic reactions or other problems… Talk to your 
pharmacist for more details. This medication should not be used if you have 
certain medical conditions. Before using this medication, tell your doctor or 
pharmacist your medical history…  Before having surgery, tell your doctor or 
dentist that you are taking this medication. Your doctor may instruct you to stop 
[DRUG] prior to surgery… Discuss the risks and benefits with your doctor. It is 
not known whether this drug passes into breast milk. Breast-feeding is not 
recommended while using this drug. Consult your doctor before breast-feeding...” 
 
Criterion 5 is “symptoms of serious or frequent adverse reactions and what to do.”  
The recall results for this are quite variable.  Most drugs listed in the top 35 filled 
prescription drugs in the U.S. do not have common frequent adverse reactions.  The drugs 
that do have common adverse reactions had a high recall, while others with rare adverse 
reactions had a low recall.  This is because the FDA mandates that every adverse reaction 
documented with this drug be present in the Package Insert, but not in the CMI Leaflet. 
Criterion 6 is “general information and encouragement to ask questions.”  This 
criterion also showed a large variation in recall.  While there is no section in the PI for 
“encouragement to ask questions”, general information is found in the Clinical 
Pharmacology section.  As most of the information found in this section of the PI is not 
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particularly useful for consumers, recall is expected to be quite low.  However, in 
Package Inserts with less clinical data presented, CMI Leaflets are able to intersect the 
main concepts with a higher recall percentage.  
Criterion 8, “comprehensibility and legibility”, was measured by using the Flesch-
Kincaid grade level score.  As shown in Figure 8, reading levels are vastly different 
between the Leaflet and Package Insert documents.  This result is consistent with 
expectations, as the PI and CMI Leaflets have different intended audiences. 
In this experiment, the Leaflets were drawn from a single source, First Databank.  
This may explain the relative consistency of the grade level scores, 73% of which fall 
between 8th and 9th grade reading levels.  Leaflets falling out of this range typically 
tracked upward in grade level to a maximum of grade level 10.5.  The Leaflets with the 
higher grade level score also correlated to medications which scored lower in CUI 
intersections for Keystone Criterion 1-6. 
Package Inserts were rated with a maximum grade level score of 16.5, which 
would, in theory, challenge graduate students' reading comprehension.  The range of 
grade levels, as shown in Figure 8, is slightly more diverse than what is found in CMI 
Leaflets, but also follows the same trend of difficulty based on the drug.  Drugs which 
have longer, more complicated sets of instructions, warnings, and other facts seem to 
reflect higher grade level scores in both the Package Insert and the CMI Leaflet, as 
exemplified by Synthroid, the synthetic thyroid hormone, and Lexapro, an antidepressant. 
Generic drugs are produced by different manufacturers under the same drug 
names.  Since each manufacturer is responsible for writing their own PI, the information 
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could potentially be different between manufacturers.  Surprisingly, there was a great 
deal of variation between the PI documentation between manufacturers of the same 
generic drug, particularly in reading level, as shown in Figure 8. 
 The readability goal of the 8th grade level as a target for the Leaflet data provider 
in the study was not met exactly, but it was close.  Forty-three percent of the CMI 
Leaflets for the top 35 drugs were at or below the 8th grade reading level.  A modest 
effort to simplify the text would likely open up this information to more of the 
population. 
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SUMMARY AND CONCLUSIONS 
 
 Through examining recall of CUI terms in Package Inserts in from CMI Leaflets, 
it was found that there was a fairly low recall percentage between the two documents.  
However, this is to be expected, as the CMI Leaflet is intended to be brief, factual, and 
usable, whereas the Package Insert is designed to be extremely thorough.   
The reading levels shown by the Flesch-Kincaid grade level scores are consistent.  
The rated grade level of the CMI Leaflets averaged in the 8th to 9th grade range, while the 
PI were in the 14th-15th grade range.  This result points to the readability of the CMI 
Leaflets, being easily readable by much of the U.S. population.  
Of the results obtained by this study, possibly the most telling is that Criterion 4, 
precautions and how to avoid harm using the drug, was virtually the same for many CMI 
leaflets (see Fig. 7).  Specific precautions were generally not given, rather a more generic 
statement of what to do if a reaction is noticed was given.  This supports the conclusion 
of Raynor, Svarstad, Knapp, et al. (2007), that U.S. CMI leaflets are weak in that area. 
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The Package Insert is public information which anyone can obtain, and is full of 
data which could be useful for patients.  The drug interactions omitted from CMI Leaflets 
are generally unusual and not life-threatening.  However, the danger in writing 
summaries where an individual’s well-being is potentially at stake is the possibility of 
becoming complacent about omitting information about rare effects or consequences of 
the drug. 
 This study has shown that text mining tools such as MetaMap may be able to 
evaluate drug information documents such as Package Inserts and CMI Leaflets without 
the expense of an expert evaluator.  However, there is future work to be done. 
One direction future research can go in is to compare results of an automated 
evaluation system those of a human expert evaluator.  This study did not address how an 
automated system compares to human evaluators, but this is an important issue to address 
before suggesting that text mining technology replace human evaluators for this task. 
Future research could also better examine the fundamental differences in content 
between PI and CMI Leaflets.  While this experiment shows recall and grade level 
metrics, more work can be done on what types of data are consistently shared between PI 
and CMI, and what data are missing.  For example, it may prove useful to identify 
whether or not specific information such as the effect of a drug during pregnancy or with 
other conditions reaches the patient through the CMI Leaflet. 
Lastly, the scale of this study was small, only evaluating the top 35 filled 
prescriptions in the U.S., and exclusively using First Databank as the information source 
for CMI Leaflets.  Ideally, a larger sample of drugs should be used in future studies, as 
well as a larger sample of CMI Leaflet providers, given the lower cost of automatic 
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evaluation instead of human expert evaluators. More work in automatic evaluation of 
drug information documents on a larger scale is warranted.   
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APPENDIX 
Sample MetaMap Output (Package Insert- Warfarin sodium) 
Processing 100003501.ti.1: WARFARIN SODIUM  warfarin sodium   tablet pt1 
 
Phrase: "WARFARIN SODIUM  warfarin sodium   tablet pt1" 
Meta Mapping (774): 
   660 C0376218:Warfarin Sodium [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   632 C0039225:Tablet (Tablet Dosage Form) [Biomedical or Dental Material] 
Meta Mapping (774): 
   660 C0376218:Warfarin Sodium [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   632 C1705223:Tablet (Tablet Dosing Unit) [Quantitative Concept] 
Processing 100003501.ab.1: INDICATIONS AND USAGE: Warfarin sodium tablets are indicated for the prophylaxis 
andor treatment of venous thrombosis and its extension and pulmonary embolism. 
 
Phrase: "INDICATIONS" 
Meta Mapping (1000): 
  1000 C0392360:Indications (Indication of (contextual qualifier)) [Idea or Concept] 
 
Phrase: "AND" 
Phrase: "USAGE" 
Meta Mapping (1000): 
  1000 C0457083:Usage [Functional Concept] 
 
Phrase: ":" 
 
Phrase: "Warfarin sodium tablets" 
Meta Mapping (901): 
   734 C0376218:Warfarin Sodium [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   827 C0039225:Tablets (Tablet Dosage Form) [Biomedical or Dental Material] 
 
Phrase: "are" 
 
Phrase: "indicated" 
Meta Mapping (1000): 
  1000 C1444656:Indicated [Finding] 
 
Phrase: "for the prophylaxis andor treatment" 
Meta Mapping (877): 
   877 C0199176:Prophylactic treatment [Therapeutic or Preventive Procedure] 
Phrase: "of venous thrombosis" 
Meta Mapping (1000): 
  1000 C0042487:Venous Thrombosis [Pathologic Function] 
Meta Mapping (1000): 
  1000 C0517555:Venous thrombosis (Venous thrombosis after immobility) [Finding] 
 
Phrase: "and" 
 
Phrase: "its extension" 
Meta Mapping (1000): 
  1000 C0231448:Extension [Functional Concept] 
Meta Mapping (1000): 
  1000 C1880641:Extension (Telephone Extension Number) [Conceptual Entity] 
 
Phrase: "and" 
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Phrase: "pulmonary embolism." 
Meta Mapping (1000): 
  1000 C0034065:Pulmonary Embolism [Disease or Syndrome] 
Processing 100003501.ab.2: Warfarin sodium tablets are indicated for the prophylaxis andor treatment of the 
thromboembolic complications associated with atrial fibrillation andor cardiac valve replacement. 
Phrase: "Warfarin sodium tablets" 
Meta Mapping (901): 
   734 C0376218:Warfarin Sodium [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   827 C0039225:Tablets (Tablet Dosage Form) [Biomedical or Dental Material] 
 
Phrase: "are" 
 
Phrase: "indicated" 
Meta Mapping (1000): 
  1000 C1444656:Indicated [Finding] 
 
Phrase: "for the prophylaxis andor treatment" 
Meta Mapping (877): 
   877 C0199176:Prophylactic treatment [Therapeutic or Preventive Procedure] 
 
Phrase: "of the thromboembolic complications" 
Meta Mapping (888): 
   694 C0333214:Thromboembolic [Functional Concept] 
   861 C0009566:Complications (Complication) [Pathologic Function] 
Meta Mapping (888): 
   694 C0333214:Thromboembolic [Functional Concept] 
   861 C1171258:complications (Complication Aspects) [Pathologic Function] 
Phrase: "associated" 
Meta Mapping (1000): 
  1000 C0332281:Associated (Associated with) [Qualitative Concept] 
 
Phrase: "with atrial fibrillation andor cardiac valve replacement." 
Meta Mapping (786): 
   660 C0004238:Atrial Fibrillation [Pathologic Function] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C1555302:Replacement (Act Code - Replacement) [Idea or Concept] 
Meta Mapping (786): 
   660 C0004238:Atrial Fibrillation [Pathologic Function] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0559956:Replacement [Functional Concept] 
Meta Mapping (786): 
   660 C0004238:Atrial Fibrillation [Pathologic Function] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0035139:Replacement (Surgical Replantation) [Therapeutic or Preventive Procedure] 
Meta Mapping (786): 
   660 C1963067:Atrial fibrillation (Atrial Fibrillation Adverse Event) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C1555302:Replacement (Act Code - Replacement) [Idea or Concept] 
Meta Mapping (786): 
   660 C1963067:Atrial fibrillation (Atrial Fibrillation Adverse Event) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0559956:Replacement [Functional Concept] 
Meta Mapping (786): 
   660 C1963067:Atrial fibrillation (Atrial Fibrillation Adverse Event) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0035139:Replacement (Surgical Replantation) [Therapeutic or Preventive Procedure] 
Meta Mapping (786): 
   660 C2108067:atrial fibrillation (continuous electrocardiogram atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C1555302:Replacement (Act Code - Replacement) [Idea or Concept] 
Meta Mapping (786): 
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   660 C2108067:atrial fibrillation (continuous electrocardiogram atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0559956:Replacement [Functional Concept] 
Meta Mapping (786): 
   660 C2108067:atrial fibrillation (continuous electrocardiogram atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0035139:Replacement (Surgical Replantation) [Therapeutic or Preventive Procedure] 
Meta Mapping (786): 
   660 C2041124:atrial fibrillation (electrocardiogram rhythm strip 3-lead atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C1555302:Replacement (Act Code - Replacement) [Idea or Concept] 
Meta Mapping (786): 
   660 C2041124:atrial fibrillation (electrocardiogram rhythm strip 3-lead atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0559956:Replacement [Functional Concept] 
Meta Mapping (786): 
   660 C2041124:atrial fibrillation (electrocardiogram rhythm strip 3-lead atrial fibrillation) [Finding] 
   660 C0018826:Cardiac valve (Heart Valves) [Body Part, Organ, or Organ Component] 
   799 C0035139:Replacement (Surgical Replantation) [Therapeutic or Preventive Procedure] 
Processing 100003501.ab.3: Warfarin sodium tablets are indicated to reduce the risk of death recurrent myocardial 
infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction. 
 
Phrase: "Warfarin sodium tablets" 
Meta Mapping (901): 
   734 C0376218:Warfarin Sodium [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   827 C0039225:Tablets (Tablet Dosage Form) [Biomedical or Dental Material] 
 
 
… 
 
Sample MetaMap Output (First Databank Leaflet- Warfarin sodium) 
Processing 212600001.ti.1: WARFARIN - ORAL FDB pt1 
 
Phrase: "WARFARIN - ORAL FDB pt1" 
Meta Mapping (775): 
   645 C0043031:Warfarin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   645 C0442027:Oral [Spatial Concept] 
Processing 212600001.ab.1: COMMON BRAND NAME(S):Coumadin WARNING:Warfarin can cause very serious 
(possibly fatal) bleeding. 
 
Phrase: "COMMON BRAND NAME" 
Meta Mapping (623): 
   660 C0205214:Common (Common (qualifier value)) [Quantitative Concept] 
   660 C0645690:BrAnd (3-bromoacetoxyandrostan-17-one) [Pharmacologic Substance,Steroid] 
Meta Mapping (623): 
   660 C1522138:Common (shared attribute) [Functional Concept] 
   660 C0645690:BrAnd (3-bromoacetoxyandrostan-17-one) [Pharmacologic Substance,Steroid] 
 
Phrase: "(S):Coumadin WARNING" 
Meta Mapping (660): 
   660 C0699129:Coumadin [Organic Chemical,Pharmacologic Substance] 
 
Phrase: ":" 
 
Phrase: "Warfarin" 
Meta Mapping (1000): 
  1000 C0043031:Warfarin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
 
Phrase: "can" 
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Phrase: "cause" 
Meta Mapping (1000): 
  1000 C1524003:Cause (Science of Etiology) [Conceptual Entity] 
 
Phrase: "very serious" 
Meta Mapping (888): 
   694 C0442824:Very [Qualitative Concept] 
   861 C0205404:Serious [Qualitative Concept] 
 
Phrase: "(possibly fatal" 
Meta Mapping (888): 
   694 C0332149:POSSIBLY (Possible) [Qualitative Concept] 
   861 C1705232:FATAL (Death Related to Adverse Event) [Finding] 
Meta Mapping (888): 
   694 C0332149:POSSIBLY (Possible) [Qualitative Concept] 
   861 C1302234:Fatal [Qualitative Concept] 
Meta Mapping (888): 
   694 C2362652:Possibly (Possible diagnosis) [Qualitative Concept] 
   861 C1705232:FATAL (Death Related to Adverse Event) [Finding] 
Meta Mapping (888): 
   694 C2362652:Possibly (Possible diagnosis) [Qualitative Concept] 
   861 C1302234:Fatal [Qualitative Concept] 
 
Phrase: ")" 
 
Phrase: "bleeding." 
Meta Mapping (1000): 
  1000 C0019080:Bleeding (Hemorrhage) [Finding] 
Processing 212600001.ab.2: This is more likely to occur when you first start taking this medication and/or when you 
are taking too much warfarin. 
 
Phrase: "This" 
 
Phrase: "is" 
 
Phrase: "more likely to" 
Meta Mapping (827): 
   827 C0332148:Likely (Probable diagnosis) [Qualitative Concept] 
 
Phrase: "occur" 
Meta Mapping (1000): 
  1000 C1709305:Occur [Conceptual Entity] 
 
Phrase: "when" 
 
Phrase: "you first" 
Meta Mapping (1000): 
  1000 C0205435:First (First (number)) [Quantitative Concept] 
Meta Mapping (1000): 
  1000 C1279901:First (Firstly) [Qualitative Concept] 
 
Phrase: "start" 
Meta Mapping (966): 
   966 C1272689:Started [Qualitative Concept] 
 
Phrase: "taking" 
Meta Mapping (966): 
   966 C1883727:Taken [Conceptual Entity] 
 
Phrase: "this medication" 
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Meta Mapping (1000): 
  1000 C0013227:Medication, NOS (Pharmaceutical Preparations) [Pharmacologic Substance] 
 
Phrase: "and/or" 
 
Phrase: "when" 
 
Phrase: "you" 
 
Phrase: "are" 
Phrase: "taking" 
Meta Mapping (966): 
   966 C1883727:Taken [Conceptual Entity] 
 
Phrase: "too" 
 
Phrase: "much warfarin." 
Meta Mapping (1000): 
  1000 C0043031:Warfarin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
Processing 212600001.ab.3: To decrease your risk for bleeding, your doctor or other health care provider will monitor 
you closely and check your lab results (INR test) to make sure you are not taking too much warfarin. 
 
Phrase: "To" 
 
Phrase: "decrease" 
Meta Mapping (1000): 
  1000 C0547047:Decrease [Quantitative Concept] 
Meta Mapping (1000): 
  1000 C0392756:Decrease (Reduced) [Qualitative Concept] 
 
Phrase: "your risk" 
Meta Mapping (1000): 
  1000 C0035647:Risk [Qualitative Concept] 
 
Phrase: "for bleeding," 
Meta Mapping (1000): 
  1000 C0019080:Bleeding (Hemorrhage) [Finding] 
 
Phrase: "your doctor" 
Meta Mapping (1000): 
  1000 C2348314:Doctor (Doctor - Title) [Conceptual Entity] 
 
Phrase: "or" 
 
Phrase: "other health care provider" 
Meta Mapping (851): 
   612 C1955473:Others [Finding] 
   694 C0086388:Health Care [Health Care Activity] 
   812 C1555587:provider (Act Code - provider) [Idea or Concept] 
Meta Mapping (851): 
   612 C1955473:Others [Finding] 
   694 C0086388:Health Care [Health Care Activity] 
   812 C1441436:{Provider} [Health Care Activity] 
 
Phrase: "will" 
 
Phrase: "monitor" 
Meta Mapping (1000): 
  1000 C0181904:Monitor (Biomedical Monitors) [Medical Device] 
Meta Mapping (1000): 
  1000 C1704646:Monitor (Monitor Device Component) [Manufactured Object] 
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Meta Mapping (1000): 
  1000 C0596972:Monitor (Monitoring Device) [Medical Device] 
 
Phrase: "you closely" 
Meta Mapping (928): 
   928 C0587267:Close (Closed) [Functional Concept] 
Meta Mapping (928): 
   928 C1522666:Closest [Spatial Concept] 
 
Phrase: "and" 
 
Phrase: "check" 
Meta Mapping (1000): 
  1000 C1948051:Check (Checking) [Qualitative Concept] 
 
Phrase: "your lab results" 
Meta Mapping (870): 
   661 C0237076:Labs (Laboratory Finding) [Laboratory or Test Result] 
   861 C1274040:Results (result) [Functional Concept] 
 
Phrase: "(INR test" 
Meta Mapping (1000): 
  1000 C0851084:INR test [Laboratory Procedure] 
 
Phrase: ")" 
 
Phrase: "to" 
 
Phrase: "make" 
Meta Mapping (1000): 
  1000 C1881534:Make (Make - Instruction Imperative) [Functional Concept] 
 
Phrase: "sure you" 
 
Phrase: "are" 
 
Phrase: "not" 
Meta Mapping (1000): 
  1000 C1518422:Not (Negation) [Functional Concept] 
 
Phrase: "taking" 
Meta Mapping (966): 
   966 C1883727:Taken [Conceptual Entity] 
 
Phrase: "too" 
 
Phrase: "much warfarin." 
Meta Mapping (1000): 
  1000 C0043031:Warfarin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
Processing 212600001.ab.4: Keep all medical and laboratory appointments. 
 
Phrase: "Keep" 
Phrase: "all medical" 
Meta Mapping (1000): 
  1000 C0205476:Medical [Functional Concept] 
 
Phrase: "and" 
 
Phrase: "laboratory appointments." 
Meta Mapping (861): 
   861 C0003629:Appointments [Idea or Concept] 
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Processing 212600001.ab.5: Tell your doctor immediately if you notice any signs of serious bleeding. 
 
Phrase: "Tell" 
 
Phrase: "your doctor immediately" 
Meta Mapping (861): 
   861 C2348314:Doctor (Doctor - Title) [Conceptual Entity] 
 
Phrase: "if" 
 
Phrase: "you" 
 
Phrase: "notice" 
 
Phrase: "any signs" 
Meta Mapping (1000): 
  1000 C0220912:signs (Aspects of signs) [Functional Concept] 
Meta Mapping (1000): 
  1000 C0220913:Signs (Manufactured sign) [Manufactured Object] 
Meta Mapping (1000): 
  1000 C0311392:SIGNS (Physical findings) [Finding] 
 
Phrase: "of serious bleeding." 
Meta Mapping (888): 
   694 C0205404:Serious [Qualitative Concept] 
   861 C0019080:Bleeding (Hemorrhage) [Finding] 
Processing 212600001.ab.6: See also Side Effects section. 
 
Phrase: "See" 
Meta Mapping (966): 
   966 C0205397:Seen [Qualitative Concept] 
Meta Mapping (966): 
   966 C0183089:SAW (saw (device)) [Medical Device] 
 
Phrase: "also Side Effects" 
Meta Mapping (901): 
   901 C0879626:side effects (Adverse effects) [Pathologic Function] 
Meta Mapping (901): 
   901 C0001688:side effects (aspects of adverse effects) [Functional Concept] 
 
Phrase: "section." 
Meta Mapping (1000): 
  1000 C1293097:Section, NOS (Division (procedure)) [Therapeutic or Preventive Procedure] 
Meta Mapping (1000): 
  1000 C0205155:Section (Sectional Distribution) [Spatial Concept] 
Meta Mapping (1000): 
  1000 C1552923:Section (Square Mile) [Quantitative Concept] 
Meta Mapping (1000): 
  1000 C1522472:Section (section sample) [Substance] 
Processing 212600002.ti.1: WARFARIN - ORAL FDB pt2 
 
Phrase: "WARFARIN - ORAL FDB pt2" 
Meta Mapping (775): 
   645 C0043031:Warfarin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance] 
   645 C0442027:Oral [Spatial Concept] 
Processing 212600002.ab.1: USES:This medication is used to treat blood clots (such as in deep vein thrombosis-DVT 
or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. 
 
Phrase: "USES" 
Meta Mapping (966): 
   966 C0457083:Use (Usage) [Functional Concept] 
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Meta Mapping (966): 
   966 C0042153:use (utilization qualifier) [Functional Concept] 
 
Phrase: ":" 
 
Phrase: "This medication" 
Meta Mapping (1000): 
  1000 C0013227:Medication, NOS (Pharmaceutical Preparations) [Pharmacologic Substance] 
 
Phrase: "is" 
 
Phrase: "used to" 
Meta Mapping (827): 
   827 C0457083:Use (Usage) [Functional Concept] 
Meta Mapping (827): 
   827 C1524063:Using (Use of) [Functional Concept] 
Meta Mapping (827): 
   827 C0042153:use (utilization qualifier) [Functional Concept] 
 
Phrase: "treat" 
Meta Mapping (1000): 
  1000 C1522326:Treat (Treating) [Functional Concept]… 
